PMID- 35465644 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2040-6207 (Print) IS - 2040-6215 (Electronic) IS - 2040-6207 (Linking) VI - 13 DP - 2022 TI - The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain. PG - 20406207221082043 LID - 10.1177/20406207221082043 [doi] LID - 20406207221082043 AB - INTRODUCTION: Bortezomib has been reported to favourably impact the outcomes of t(4;14) and del(17p) in multiple myeloma (MM), but its impact on gain 1q (+1q) is unknown. METHODS: To address this, 250 patients treated with bortezomib-based induction were analysed. All myeloma samples had fluorescence in situ hybridization (FISH) performed on CD138-sorted bone marrow aspirate, and plasma cells were analysed using DNA probes specific for the following chromosomal aberrations: del(13q14), del(17p), t(14;16), t(4;14), and +1q. Presence of +1q was defined as the presence of at least three copies of 1q21 at the cut off level of 20% of bone marrow plasma cells. RESULTS: +1q identified in 167 (66.8%) and associated with t(4;14) and high lactate dehydrogenase (LDH). +1q was not associated with response rate but shorter event-free survival (EFS) (median EFS 35 vs 55 months, p = 0.05) and overall survival (OS) (median OS 74 vs 168 months, p = 0.00025). Copy number and clone size did not impact survival. Multivariate analysis showed +1q was an independent adverse factor for OS together with International Staging System (ISS)3, high LDH, del(17p) and t(4;14). When a risk score of 1 was assigned to each independent adverse factor, OS was shortened incrementally by a risk score from 0 to 4. Post-relapse/progression survival was inferior in those with +1q (median 60 vs 118 months, p = 0.000316). Autologous stem cell transplantation (ASCT) improved OS for those with +1q (median OS 96 vs 49 months, p = 0.000069). CONCLUSION: +1q is an adverse factor for OS in MM uniformly treated with bortezomib-based induction but was partially mitigated by ASCT. A risk scoring system comprising +1q, LDH, high-risk FISH, and ISS is a potential tool for risk stratification in MM. CI - (c) The Author(s), 2022. FAU - Tang, Hoi Ki Karen AU - Tang HKK AD - Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam Road, Hong Kong. FAU - Fung, Chi Yeung AU - Fung CY AD - Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam Road, Hong Kong. FAU - Morgan, Gareth J AU - Morgan GJ AD - Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. FAU - Kumar, Shaji AU - Kumar S AUID- ORCID: 0000-0001-5392-9284 AD - Division of Hematology, Mayo Clinic, Rochester, MN, USA. FAU - Siu, Lisa AU - Siu L AD - Department of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong. FAU - Ip, Ho Wan Alvin AU - Ip HWA AD - Department of Pathology, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam Road, Hong Kong. FAU - Yip, Sze Fai AU - Yip SF AD - Department of Medicine, Tuen Mun Hospital, Tuen Mun, Hong Kong. FAU - Lau, Ka Ngai Harry AU - Lau KNH AD - Department of Pathology, Tuen Mun Hospital, Tuen Mun, Hong Kong. FAU - Lau, Chi Kuen AU - Lau CK AD - Department of Medicine, Tseung Kwan O Hospital, Kowloon, Hong Kong. FAU - Lee, Harold AU - Lee H AD - Department of Medicine, Princess Margaret Hospital, Kowloon, Hong Kong. FAU - Leung, Kwan Hung AU - Leung KH AD - Department of Medicine, United Christian Hospital, Kowloon, Hong Kong. FAU - Kho, Bonnie AU - Kho B AD - Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong. FAU - Wong, Howard AU - Wong H AD - Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong. FAU - Ngai, Cheong AU - Ngai C AD - Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam Road, Hong Kong. FAU - Hwang, Yu Yan AU - Hwang YY AD - Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam Road, Hong Kong. FAU - Sim, Joycelyn AU - Sim J AD - Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam Road, Hong Kong. FAU - Kwong, Yok Lam AU - Kwong YL AD - Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pok Fu Lam Road, Hong Kong. FAU - Chim, Chor Sang AU - Chim CS AUID- ORCID: 0000-0003-2427-915X AD - Department of Medicine, Queen Mary Hospital, University of Hong Kong, Queen Mary Hospital, Pok Fu Lam Road, Hong Kong Department of Medicine, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong. LA - eng PT - Journal Article DEP - 20220418 PL - England TA - Ther Adv Hematol JT - Therapeutic advances in hematology JID - 101549589 PMC - PMC9019371 OTO - NOTNLM OT - chromosomal aberrations OT - fluorescence in situ hybridization OT - gain 1q OT - multiple myeloma OT - risk stratification COIS- Conflict of interest statement: The authors declared no potential conflict of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/04/26 06:00 MHDA- 2022/04/26 06:01 PMCR- 2022/04/18 CRDT- 2022/04/25 05:54 PHST- 2021/09/01 00:00 [received] PHST- 2022/02/04 00:00 [accepted] PHST- 2022/04/25 05:54 [entrez] PHST- 2022/04/26 06:00 [pubmed] PHST- 2022/04/26 06:01 [medline] PHST- 2022/04/18 00:00 [pmc-release] AID - 10.1177_20406207221082043 [pii] AID - 10.1177/20406207221082043 [doi] PST - epublish SO - Ther Adv Hematol. 2022 Apr 18;13:20406207221082043. doi: 10.1177/20406207221082043. eCollection 2022.